News about Global Pharma

Exothera Welcomes Cedric Volanti as New CEO

Cédric Volanti brings a wealth of experience and a strong strategic vision.

Global Pharma | 09/10/2024 | By Aishwarya |  521

Innovent Partners with Ask Pharm for Limertinib for Treatment of Lung Cancer

Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib in mainland China, and will be entitled to receive a commercialization service fee based on the product's net sales in the region.

Global Pharma | 08/10/2024 | By Aishwarya |  623

OneSource Unveils New Brand Identity at CPHI Milan

OneSource’s end-to-end offering across all its platforms was established in response to its customers’ need to streamline supply chains by consolidating their outsourcing partners.

Global Pharma | 08/10/2024 | By Aishwarya |  1005

ABL Bio Signs Clinical Alliance with MSD to Evaluate ABL103 with KEYTRUDA

Under the terms of the agreement, ABL Bio will conduct a phase 1b/2 clinical trial to evaluate the safety and efficacy of ABL103 in combination with KEYTRUDA. In this combination study, MSD will supply KEYTRUDA.

Global Pharma | 07/10/2024 | By Aishwarya |  713

Synexa Life Sciences Acquires CRO Alderley Analytical

Alderley Analytical’s services complement Synexa Life Sciences’ established capabilities in biomarker and bioanalytical assays—covering DNA, RNA, protein, cell, and tissue analysis.

Global Pharma | 07/10/2024 | By Aishwarya |  343

Alembic Pharma Gets FDA Approval for Lamotrigine Extended-Release Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lamictal XR Extended-Release Tablets, 200 mg, 250 mg, and 300 mg, of GlaxoSmithKline LLC (GSK).

Global Pharma | 07/10/2024 | By Aishwarya |  727

MD Logistics to Launch Dedicated Pharmaceutical Warehouse in Indiana

The warehouse undergoing renovations is the largest in MD's network at approximately 37,000 m2.

Global Pharma | 07/10/2024 | By Aishwarya |  798

Johnson & Johnson Submits sBLA to FDA for Approval of DARZALEX FASPRO-Based Quadruplet Regimen

The CEPHEUS study evaluated the efficacy and safety of D-VRd compared to bortezomib, lenalidomide and dexamethasone (VRd) for NDMM patients for whom ASCT was not planned as initial therapy.

Global Pharma | 01/10/2024 | By Aishwarya |  306

Trevi Therapeutics Welcomes James V. Cassella as Chief Development Officer

Jim will play an integral role in progressing Haduvio by utilizing his broad drug development experience and his proven hands-on leadership of scientific and regulatory teams through drug approvals.

Global Pharma | 01/10/2024 | By Aishwarya |  558

Piramal Pharma to Invest USD 80 Million for Expansion of Sterile Injectables Facility in Kentucky

The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new laboratory, and state-of-the-art machinery to scale clients’ products effectively.

Global Pharma | 01/10/2024 | By Aishwarya |  983